Transgender women remain at risk of prostate cancer and warrant consideration for PSA screening. However, current PSA reference ranges and guidelines are based on data from cisgender men. As these thresholds might be inappropriate in transgender women receiving gender-affirming hormones, we recommend that these patients should undergo screening for prostate cancer at regular intervals and further evaluation for PSA >1 ng/ml or rising PSA. Furthermore patient-centred dialogues should be initiated with patients to ensure awareness of prostate cancer risk.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deebel, N. A. et al. Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges. Urology 110, 166–171 (2017).
Baraban, E. et al. Prostate cancer in male-to-female transgender individuals: histopathologic findings and association with gender-affirming hormonal therapy. Am. J. Surg. Pathol. 46, 1650–1658 (2022).
Gooren, L. & Morgentaler, A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 46, 1156–1160 (2014).
Nik-Ahd, F. et al. Prostate cancer in transgender women in the Veterans Affairs Health System, 2000–2022. JAMA https://doi.org/10.1001/jama.2023.6028 (2023).
Di Zazzo, E., Galasso, G., Giovannelli, P., Di Donato, M. & Castoria, G. Estrogens and their receptors in prostate cancer: therapeutic implications. Front. Oncol. 8, 2 (2018).
Carter, H. B. et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 190, 419–426 (2013).
Preston, M. A. et al. Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in Black men. Eur. Urol. 75, 399–407 (2019).
Hudak, S. J., Hernandez, J. & Thompson, I. M. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin. Interv. Aging 1, 425–431 (2006).
Pitak-Arnnop, P., Messer-Peti, R., Tangmanee, C., Neff, A. & Meningaud, J.-P. Prostate cancer awareness among transgender women after gender-affirming surgery. Prostate 82, 1060–1067 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Nik-Ahd, F., Anger, J.T., Cooperberg, M.R. et al. Prostate cancer is not just a man’s concern — the use of PSA screening in transgender women. Nat Rev Urol 20, 323–324 (2023). https://doi.org/10.1038/s41585-023-00780-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-023-00780-9